Torok D S, Ziffer H, Meshnick S R, Pan X Q, Ager A
National Institutes of Health, Bethesda, Maryland 20892-0510, USA.
J Med Chem. 1995 Dec 22;38(26):5045-50. doi: 10.1021/jm00026a012.
A two-step reaction sequence between artemisinin and methanolic ammonia followed by treatment with Amberlyst 15 yielded 11-azaartemisinin in 65% yield. Substituting a variety of primary alkyl- and heteroaromatic amines for ammonia in the reaction sequence yields N-substituted 11-azaartemisinins in similar or greater yield. When Amberlyst 15 is replaced by a mixture of sulfuric acid/silica gel, both 11-azaartemisinin and the expected metabolite, 10-azadesoxyartemisinin, are formed in 45% and 15% yields, respectively. In vitro and in vivo test data for a number of novel N-substituted 11-azaartemisinins, against drug-resistant strains of Plasmodium falciparum, show they possess antimalarial activities equal to or greater than that of artemisinin. The most active derivative, N-(2'-acetaldehydo)-11-azaartemisinin, 17, was 26 times more active in vitro and 4 times more active in vivo than artemisinin.
青蒿素与甲醇氨进行两步反应序列,随后用Amberlyst 15处理,以65%的产率得到11-氮杂青蒿素。在反应序列中用各种伯烷基胺和杂芳族胺代替氨,可得到产率相似或更高的N-取代的11-氮杂青蒿素。当用硫酸/硅胶混合物代替Amberlyst 15时,11-氮杂青蒿素和预期的代谢产物10-氮杂脱氧青蒿素分别以45%和15%的产率形成。一些新型N-取代的11-氮杂青蒿素针对恶性疟原虫耐药菌株的体外和体内试验数据表明,它们具有与青蒿素相当或更强的抗疟活性。活性最高的衍生物N-(2'-乙醛基)-11-氮杂青蒿素(17)在体外的活性比青蒿素高26倍,在体内高4倍。